clinical trial · NCT07226843
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Eli Lilly and Company·phase1·recruiting·n = 460
Lymphoma, Non-Hodgkin'sLymphoma, Diffuse Large B-CellFollicular LymphomaLY4584180Rituximab
brief summary
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
started
Apr 17, 2026
primary completion
Apr 1, 2027
completion
Feb 1, 2030
last updated
Aug 6, 2026
official title
NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol